|
ANKRD5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.49034126653669E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.94244661758603E-12 |
| Normal-vs-Stage2 |
3.600400E-02 |
| Normal-vs-Stage3 |
7.43849426498855E-15 |
| Normal-vs-Stage4 |
1.18793863634892E-14 |
| Stage1-vs-Stage2 |
2.017500E-02 |
| Stage1-vs-Stage3 |
6.499800E-02 |
| Stage1-vs-Stage4 |
4.362800E-03 |
| Stage2-vs-Stage3 |
2.300200E-03 |
| Stage2-vs-Stage4 |
4.049000E-04 |
| Stage3-vs-Stage4 |
3.146400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
9.837600E-04 |
| Normal-vs-Asian |
1.6592283103023E-12 |
| Caucasian-vs-AfricanAmerican |
5.259000E-01 |
| Caucasian-vs-Asian |
1.065210E-01 |
| AfricanAmerican-vs-Asian |
2.193000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.32670002656243E-10 |
| Normal-vs-Female |
2.02771133217539E-12 |
| Male-vs-Female |
9.917400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.96769292368526E-12 |
| Normal-vs-Age(41-60Yrs) |
8.6201046300971E-11 |
| Normal-vs-Age(61-80Yrs) |
1.29759999967227E-07 |
| Normal-vs-Age(81-100Yrs) |
2.770500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.335000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.966420E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.269200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.982960E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.772600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.307000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.318800E-03 |
| Classical-VS-Follicular |
1.05790000004546E-06 |
| Classical-VS-Other |
1.432760E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
4.98620034150576E-10 |
| Tall-VS-Other |
7.875200E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
6.06100000000165E-05 |
| Follicular-VS-Normal |
2.272400E-02 |
| Other-VS-Normal |
2.74120000032241E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.57309999471167E-08 |
| Normal-vs-N1 |
1.84086079713097E-12 |
| N0-vs-N1 |
4.679200E-03 |
|
|
